TUC-S.R.L.
15.5.2024 11:34:35 CEST | Business Wire | Press release
Just over a month after the Digital World Premiere, TUC.tiny is ready to make its debut at VivaTech 2024, the most important technology fair in Europe. In Hall 1, Pavilion 41, TUC S.r.l. will present to the public for the first time its latest technological innovation: TUC.tiny®, the Modular Dashboard concept, and the TUC.technology offering, developed to revolutionize the world of mobility.
TUC.tiny® is the compact version of the industrialized technology launched last year, based on the TUC.technology® patent and released in over 140 countries. It is currently the subject of collaborations with industry leaders such as ZER01NE, the Hyundai Motor Group's Open Innovation Platform, for the development of "Human-centric" vehicles.
This technological gem is based on the three pillars of TUC: mechanical structure, electronic management, and data exchange. Thanks to the integration of USB Type-C technology, TUC.tiny® aims to reinvent the interaction between users and vehicles, converging mobility and everyday life.
The result of advanced research by TUC S.r.l. in technological miniaturization and simplification, TUC.tiny® represents the core of the company's patented technology, designed to innovate the value chain in the mobility sector with a "human-centric" approach. It is an ideal solution for both the main players in the sector and users, representing a perfect synthesis of their needs.
The Modular Dashboard, developed to showcase the potential of TUC.tiny®, is a true blank canvas, customizable infinite times thanks to TUC.tiny® and TUC.technology®. An environment to inhabit and configure without limits, adapting functionally and flexibly to the needs of users.
With TUC.tiny® and its advanced interface - including physical fastening, electrical connectivity, and data transfer - any device can be integrated into the modular dashboard design, making it immediately operational. TUC.tiny® supports all everyday devices with USB Type-C connection, distinguishing itself by seamlessly blending into any part of the vehicle. Its robustness is ensured by a mechanical or electro-actuated locking mechanism, introducing the novelty of NFC technology for added security.
The introduction of TUC.tiny® completes the TUC.technology® offering, marking a step forward towards the democratization of technology. The gateway to an advanced mobility experience becomes wider, easily accommodating the smart objects that animate our daily lives.
TUC.tiny® and TUC.technology® embody the vision of the mobility ecosystem of the future: interconnected, multimodal, circular, and dynamic. This technology not only connects but synthesizes different spheres of our lives, making mobility more accessible, customizable, and environmentally conscious.
TUC invites everyone to imagine and build together a world where technology unites us, improving every aspect of our daily journey. The project, which started in the automotive sector, now aims to scale the technology to new verticals such as aerospace and marine sectors.
“The World Premiere of TUC.tiny® at VivaTech 2024 is an important recognition for TUC.technology as an enabler of the Mobility of the Future," said Ludovico Campana, Inventor and CEO of TUC. “TUC.tiny® represents our promise for the future: the vision of a world where technology and mobility create personalized experiences designed around the needs of each individual. This is the future that TUC S.r.l. is building: a mobility ecosystem driven by the values of democratization, personalization, and sustainability."
TUC.tiny® and the Modular Dashboard are ready to be showcased live to the public at VivaTech 2024, demonstrating that this vision is already a reality.
For more information, visit the "NEWSROOM" section of the website: https://www.tuc.technology/newsroom.
ABOUT TUC.technology
TUC S.r.l. is a leading Deep-Tech company in mobility innovation, specializing in the development of modular solutions for vehicles that aim to simplify and revolutionize the concept of a vehicle. Distinguished by technological excellence on an international level, TUC has received significant recognitions, including exhibitions at CES in Las Vegas and the National Automobile Museum.
With the launch of TUC 3.0, the company sets new standards in the sector, collaborating with major global OEMs. Learn more at http://www.tuc.technology.
Facebook @TUCtechnology
Instagram @tuc.technology
Twitter @TUCtechnology
Linkedin @TUC.technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515972855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom